Usefulness of Comprehensive Genomic Profiling in Clinical Decision-Making in Oncology: A Systematic Review.

Q3 Medicine Journal of Immunotherapy and Precision Oncology Pub Date : 2025-01-14 eCollection Date: 2025-02-01 DOI:10.36401/JIPO-24-11
Sewanti Limaye, Jayesh Deshmukh, Nitesh Rohatagi, Kumar Prabhash, Amit Rauthan, Shambhavi Singh, Arun Kumar
{"title":"Usefulness of Comprehensive Genomic Profiling in Clinical Decision-Making in Oncology: A Systematic Review.","authors":"Sewanti Limaye, Jayesh Deshmukh, Nitesh Rohatagi, Kumar Prabhash, Amit Rauthan, Shambhavi Singh, Arun Kumar","doi":"10.36401/JIPO-24-11","DOIUrl":null,"url":null,"abstract":"<p><p>Biologic factors limiting responsiveness to matched targeted therapies include genomic heterogeneity and complexity. Advanced tumors with unique molecular profiles can be studied by comprehensive genomic profiling (CGP) and enhance patient outcomes using principles of precision medicine. The clinical utility of CGP across all cancer types and different therapeutic interventions using overall survival (OS) and progression-free survival (PFS) data was studied in this systematic literature review. Randomized controlled, nonrandomized, and observational studies conducted in adult patients with advanced cancer, dated up to September 2022, were searched from PubMed and EMBASE databases following PRISMA guidelines. Of 14 CGP studies, 7 (50%) and 9 (64%) reported OS and PFS as an outcome, respectively. Improved OS and PFS were reported when CGP guided treatment decisions, but its clinical utility varied among cancer types. Treatments were assigned based on matching scores and with the involvement of molecular tumor board (MTB) enhanced OS and PFS. Patients following MTB recommendations had superior treatment outcomes compared with those on physician's choice regimens. CGP clinically benefited patients with genomically matched therapies and yielded better clinical outcomes regardless of cancer type. Further, uniform clinical value-based ranking of actionable mutations can encourage oncologists to use CGP tests for patients.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"8 1","pages":"55-63"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728381/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Immunotherapy and Precision Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36401/JIPO-24-11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Biologic factors limiting responsiveness to matched targeted therapies include genomic heterogeneity and complexity. Advanced tumors with unique molecular profiles can be studied by comprehensive genomic profiling (CGP) and enhance patient outcomes using principles of precision medicine. The clinical utility of CGP across all cancer types and different therapeutic interventions using overall survival (OS) and progression-free survival (PFS) data was studied in this systematic literature review. Randomized controlled, nonrandomized, and observational studies conducted in adult patients with advanced cancer, dated up to September 2022, were searched from PubMed and EMBASE databases following PRISMA guidelines. Of 14 CGP studies, 7 (50%) and 9 (64%) reported OS and PFS as an outcome, respectively. Improved OS and PFS were reported when CGP guided treatment decisions, but its clinical utility varied among cancer types. Treatments were assigned based on matching scores and with the involvement of molecular tumor board (MTB) enhanced OS and PFS. Patients following MTB recommendations had superior treatment outcomes compared with those on physician's choice regimens. CGP clinically benefited patients with genomically matched therapies and yielded better clinical outcomes regardless of cancer type. Further, uniform clinical value-based ranking of actionable mutations can encourage oncologists to use CGP tests for patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
综合基因组谱分析在肿瘤学临床决策中的作用:一项系统综述。
限制匹配靶向疗法反应性的生物学因素包括基因组异质性和复杂性。具有独特分子特征的晚期肿瘤可通过全面基因组图谱分析(CGP)进行研究,并利用精准医疗原则提高患者的预后。本系统性文献综述利用总生存期(OS)和无进展生存期(PFS)数据研究了CGP在所有癌症类型和不同治疗干预中的临床效用。按照PRISMA指南,从PubMed和EMBASE数据库中检索了截至2022年9月针对晚期癌症成年患者进行的随机对照、非随机和观察性研究。在14项CGP研究中,分别有7项(50%)和9项(64%)报告了OS和PFS结果。CGP指导治疗决策时,OS和PFS均有改善,但其临床效用因癌症类型而异。根据匹配评分分配治疗方案,并在分子肿瘤委员会(MTB)的参与下可提高OS和PFS。与医生选择的治疗方案相比,听从分子肿瘤委员会建议的患者治疗效果更好。无论癌症类型如何,CGP 都能使接受基因组匹配疗法的患者临床获益,并产生更好的临床疗效。此外,基于临床价值对可操作突变进行统一排序可鼓励肿瘤学家为患者使用 CGP 检测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
17
期刊最新文献
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial. Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study. Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial. Expert Clinical Management of Inflammatory Immune-Related Arthritis in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Usefulness of Comprehensive Genomic Profiling in Clinical Decision-Making in Oncology: A Systematic Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1